EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Morbelli, S. (Silvia); Esposito, G. (Giuseppe); Arbizu, J. (Javier); Barthel, H. (Henryk); Boellaard, R. (Ronald); Bohnen, N. (Nico); Brooks, D.J. (David J.); Darcourt, J. (Jacques); Dickson, J.C. (John C.); Douglas, D. (David); Drzezga, A. (Alexander); Dubroff, J. (Jacob); Ekmekcioglu, O. (Ozgul); Garibotto, V. (Valentina); Herscovitch, P. (Peter); Kuo, P. (Phillip); Lammertsma, A. (Adriaan); Pappata, S. (Sabina); Peñuelas-Sanchez, I. (Ivan); Seibyl, J. (John); Semah, F. (Franck); Tossici-Bolt, L. (Livia); Van-de-Giessen, E. (Elsmarieke); Van-Laere, K. (Koen); Varrone, A. (Andrea); Wanner, M. (Michele); Zubal, G. (George); Law, I. (Ian)

Keywords:

Brain
DAT
DOPA
PET
SPECT
Parkinson
Parkinsonian syndromes

Issue Date:

2020

ISSN:

1619-7070

Editorial note:

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Note:

This. article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Citation:

Morbelli, S. (Silvia); Esposito, G. (Giuseppe); Arbizu, J. (Javier); et al. "EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0". European Journal of Nuclear Medicine and Molecular Imaging. 47, 2020, 1885 - 1912

Abstract

Purpose This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes. Methods Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking. Conclusion All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.

URI:

https://hdl.handle.net/10171/66185

DOI:

10.1007/s00259-020-04817-8

Appears in Collections:

DA - CUN - Medicina nuclear - Artículos de revista

Files in This Item: